The MIQE Guidelines:
Minimum Information for Publication of Quantitative
Real-Time PCR Experiments
Stephen A. Bustin,1*
Vladimir Benes,2
Jeremy A. Garson,3,4
Jan Hellemans,5
Jim Huggett,6
Mikael Kubista,7,8
Reinhold Mueller,9
Tania Nolan,10
Michael W. Pfaffl,11
Gregory L. Shipley,12
Jo Vandesompele,5
and Carl T. Wittwer13,14
BACKGROUND: Currently, a lack of consensus exists on
how best to perform and interpret quantitative realtime
PCR (qPCR) experiments. The problem is exacerbated
by a lack of sufficient experimental detail in
many publications, which impedes a reader’s ability to
evaluate critically the quality of the results presented or
to repeat the experiments.
CONTENT: The Minimum Information for Publication
of Quantitative Real-Time PCR Experiments (MIQE)
guidelines target the reliability of results to help ensure
the integrity of the scientific literature, promote consistency
between laboratories, and increase experimental
transparency. MIQE is a set of guidelines that describe
the minimum information necessary for
evaluating qPCR experiments. Included is a checklist to
accompany the initial submission of a manuscript to
the publisher. By providing all relevant experimental
conditions and assay characteristics, reviewers can assess
the validity of the protocols used. Full disclosure of
all reagents, sequences, and analysis methods is necessary
to enable other investigators to reproduce results.
MIQE details should be published either in abbreviated
form or as an online supplement.
SUMMARY: Following these guidelines will encourage
better experimental practice, allowing more reliable
and unequivocal interpretation of qPCR results.
© 2009 American Association for Clinical Chemistry
The fluorescence-based quantitative real-time PCR
(qPCR)15
(1–3), with its capacity to detect and measure
minute amounts of nucleic acids in a wide range of
samples from numerous sources, is the enabling technology
par excellence of molecular diagnostics, life sciences,
agriculture, and medicine (4, 5). Its conceptual
and practical simplicity, together with its combination
of speed, sensitivity, and specificity in a homogeneous
assay, have made it the touchstone for nucleic acid
quantification. In addition to its use as a research tool,
many diagnostic applications have been developed, including
microbial quantification, gene dosage determination,
identification of transgenes in genetically modified
foods, risk assessment of cancer recurrence, and
applications for forensic use (6–11).
This popularity is reflected in the prodigious
number of publications reporting qPCR data, which
invariably use diverse reagents, protocols, analysis
methods, and reporting formats. This remarkable
lack of consensus on how best to perform qPCR experiments
has the adverse consequence of perpetuating
a string of serious shortcomings that encumber
its status as an independent yardstick (12). Technical
deficiencies that affect assay performance include
the following: (a) inadequate sample storage, preparation,
and nucleic acid quality, yielding highly
variable results; (b) poor choice of reverse-transcription
primersand primers and probes for the PCR, leading to
inefficient and less-than-robust assay performance;
1
Centre for Academic Surgery, Institute of Cell and Molecular Science, Barts and
the London School of Medicine and Dentistry, London, UK; 2
Genomics Core
Facility, EMBL Heidelberg, Heidelberg, Germany; 3
Centre for Virology, Department
of Infection, University College London, London, UK; 4
Department of
Virology, UCL Hospitals NHS Foundation Trust, London, UK; 5
Center for Medical
Genetics, Ghent University Hospital, Ghent, Belgium; 6
Centre for Infectious
Diseases, University College London, London, UK; 7
TATAA Biocenter, Go¨teborg,
Sweden; 8
Institute of Biotechnology AS CR, Prague, Czech Republic; 9
Sequenom,
San Diego, California, USA; 10
Sigma–Aldrich, Haverhill, UK; 11
Physiology
Weihenstephan, Technical University Munich, Freising, Germany; 12
Quantitative
Genomics Core Laboratory, Department of Integrative Biology and Pharmacology,
University of Texas Health Science Center, Houston, Texas, USA;
13
Department of Pathology, University of Utah, Salt Lake City, Utah, USA;
14
ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah,
USA.
* Address correspondence to this author at: 3rd Floor Alexandra Wing, The Royal
London Hospital, London E1 1BB, UK. Fax ϩ44-(0)20-7377 7283; e-mail
s.a.bustin@qmul.ac.uk.
Received October 20, 2008; accepted January 27, 2009.
Previously published online at DOI: 10.1373/clinchem.2008.112797
15
Nonstandard abbreviations: qPCR, quantitative real-time PCR; MIQE, Minimum
Information for Publication of Quantitative Real-Time PCR Experiments; RTqPCR,
reverse transcription–qPCR; FRET, fluorescence resonance energy transfer;
Cq, quantification cycle, previously known as the threshold cycle (Ct),
crossing point (Cp), or take-off point (TOP); RDML, Real-Time PCR Data Markup
Language; LOD, limit of detection; NTC, no-template control.
Clinical Chemistry 55:4
611–622 (2009) Special Report
611
and (c) inappropriate data and statistical analyses, generating
results that can be highly misleading. Consequently,
there is the real danger of the scientific literature
being corrupted with a multitude of publications
reporting inadequate and conflicting results ( 13). The
publication (14) and retraction (15) of a Science
“Breakthrough of the Year 2005” report provides a
disquieting warning. The problem is exacerbated by
the lack of information that characterizes most reports
of studies that have used this technology, with many
publications not providing sufficient experimental
detail to permit the reader to critically evaluate the
quality of the results presented or to repeat the experiments.
Specifically, information about sample acquisition
and handling, RNA quality and integrity, reversetranscription
details, PCR efficiencies, and analysis
parameters are frequently omitted, whereas sample
normalization is habitually carried out against single
reference genes without adequate justification.
The aim of this document is to provide authors,
reviewers, and editors specifications for the minimum
information, set out in Table 1, that must be reported
for a qPCR experiment to ensure its relevance, accuracy,
correct interpretation, and repeatability. MIQE
(Minimum Information for Publication of Quantitative
Real-Time PCR Experiments, pronounced mykee)
is modeled on similar guidelines drawn up for DNA
microarray analysis (16), proteomics experiments
(17), genome sequence specification (18), and those
under discussion for RNA interference work (19, 20)
and metabolomics (21), all of which are initiatives coordinated
under the umbrella of MIBBI (Minimum
Information for Biological and Biomedical Investigations,
http://www.mibbi.org) (22). Compulsory inclusion
of a common reporting language to allow data
sharing is not proposed, although it is envisaged that a
future update of these guidelines could include such a
recommendation. Rather, these guidelines target the
reliability of results to help ensure the integrity of the
scientific literature, promote consistency between laboratories,
and increase experimental transparency.
They should be read in conjunction with recent publications
that deal in depth with the issue of qPCR standardization
(23–26).
1. Nomenclature
A few terms require standardization to ensure
clarification:
1.1 We propose that the abbreviation qPCR be used
for quantitative real-time PCR and that RT-qPCR
be used for reverse transcription–qPCR. Applying
the abbreviation RT-PCR to qPCR causes confusion
and is inconsistent with its use for conventional
(legacy) reverse transcription–PCR.
1.2 Genes used for normalization should be referred to
as reference genes, not as housekeeping genes.
1.3 TaqMan probes should be referred to as hydrolysis
probes.
1.4 The term FRET probe (fluorescence resonance energy
transfer probe) refers to a generic mechanism
in which emission/quenching relies on the interaction
between the electron-excitation states of 2 fluorescent
dye molecules. LightCycler-type probes
should be referred to as dual hybridization probes.
1.5 The Oxford English Dictionary lists only quantification,
not quantitation; therefore, the former is the
proper word.
1.6 The nomenclature describing the fractional PCR
cycle used for quantification is inconsistent, with
threshold cycle (Ct), crossing point (Cp), and take-off
point (TOP) currently used in the literature. These
terms all refer to the same value from the real-time
instrument and were coined by competing manufacturers
of real-time instruments for reasons of
product differentiation, not scientific accuracy or
clarity. We propose the use of quantification cycle
(Cq), according to the RDML (Real-Time PCR
Data Markup Language) data standard (http://
www.rdml.org) (27).
2. Conceptual Considerations
To explain and justify the guidelines, we find it useful
to review a number of key issues surrounding qPCR
experiments:
2.1 Analytical sensitivity refers to the minimum number
of copies in a sample that can be measured
accurately with an assay, whereas clinical sensitivity
is the percentage of individuals with a given disorder
whom the assay identifies as positive for that
condition. Typically, sensitivity is expressed as the
limit of detection (LOD), which is the concentration
that can be detected with reasonable certainty
(95% probability is commonly used) with a given
analytical procedure. The most sensitive LOD theoretically
possible is 3 copies per PCR (28), assuming
a Poisson distribution, a 95% chance of including
at least 1 copy in the PCR, and single-copy
detection. Experimental procedures typically include
sample-processing steps (i.e., extraction)
and, when required, reverse transcription. If the
volume changes and the efficiencies of these steps
are accounted for, the most sensitive LOD theoretically
possible can be expressed in units relevant to
the experiment, such as copies per nanogram of
tissue. Experimental results less than the theoretiSpecial
Report
612 Clinical Chemistry 55:4 (2009)
Table 1. MIQE checklist for authors, reviewers, and editors.a
Item to check Importance Item to check Importance
Experimental design qPCR oligonucleotides
Definition of experimental and control groups E Primer sequences E
Number within each group E RTPrimerDB identification number D
Assay carried out by the core or investigator’s laboratory? D Probe sequences Dd
Acknowledgment of authors’ contributions D Location and identity of any modifications E
Sample Manufacturer of oligonucleotides D
Description E Purification method D
Volume/mass of sample processed D qPCR protocol
Microdissection or macrodissection E Complete reaction conditions E
Processing procedure E Reaction volume and amount of cDNA/DNA E
If frozen, how and how quickly? E Primer, (probe), Mg2ϩ
, and dNTP concentrations E
If fixed, with what and how quickly? E Polymerase identity and concentration E
Sample storage conditions and duration (especially for FFPEb
samples) E Buffer/kit identity and manufacturer E
Nucleic acid extraction Exact chemical composition of the buffer D
Procedure and/or instrumentation E Additives (SYBR Green I, DMSO, and so forth) E
Name of kit and details of any modifications E Manufacturer of plates/tubes and catalog number D
Source of additional reagents used D Complete thermocycling parameters E
Details of DNase or RNase treatment E Reaction setup (manual/robotic) D
Contamination assessment (DNA or RNA) E Manufacturer of qPCR instrument E
Nucleic acid quantification E qPCR validation
Instrument and method E Evidence of optimization (from gradients) D
Purity (A260/A280) D Specificity (gel, sequence, melt, or digest) E
Yield D For SYBR Green I, Cq of the NTC E
RNA integrity: method/instrument E Calibration curves with slope and y intercept E
RIN/RQI or Cq of 3Ј and 5Ј transcripts E PCR efficiency calculated from slope E
Electrophoresis traces D CIs for PCR efficiency or SE D
Inhibition testing (Cq dilutions, spike, or other) E r2
of calibration curve E
Reverse transcription Linear dynamic range E
Complete reaction conditions E Cq variation at LOD E
Amount of RNA and reaction volume E CIs throughout range D
Priming oligonucleotide (if using GSP) and concentration E Evidence for LOD E
Reverse transcriptase and concentration E If multiplex, efficiency and LOD of each assay E
Temperature and time E Data analysis
Manufacturer of reagents and catalogue numbers D qPCR analysis program (source, version) E
Cqs with and without reverse transcription Dc
Method of Cq determination E
Storage conditions of cDNA D Outlier identification and disposition E
qPCR target information Results for NTCs E
Gene symbol E Justification of number and choice of reference genes E
Sequence accession number E Description of normalization method E
Location of amplicon D Number and concordance of biological replicates D
Amplicon length E Number and stage (reverse transcription or qPCR) of technical replicates E
In silico specificity screen (BLAST, and so on) E Repeatability (intraassay variation) E
Pseudogenes, retropseudogenes, or other homologs? D Reproducibility (interassay variation, CV) D
Sequence alignment D Power analysis D
Secondary structure analysis of amplicon D Statistical methods for results significance E
Location of each primer by exon or intron (if applicable) E Software (source, version) E
What splice variants are targeted? E Cq or raw data submission with RDML D
a
All essential information (E) must be submitted with the manuscript. Desirable information (D) should be submitted if available. If primers are from RTPrimerDB,
information on qPCR target, oligonucleotides, protocols, and validation is available from that source.
b
FFPE, formalin-fixed, paraffin-embedded; RIN, RNA integrity number; RQI, RNA quality indicator; GSP, gene-specific priming; dNTP, deoxynucleoside triphosphate.
c
Assessing the absence of DNA with a no–reverse transcription assay is essential when first extracting RNA. Once the sample has been validated as DNA free,
inclusion of a no–reverse transcription control is desirable but no longer essential.
d
Disclosure of the probe sequence is highly desirable and strongly encouraged; however, because not all vendors of commercial predesigned assays provide this
information, it cannot be an essential requirement. Use of such assays is discouraged.
MIQE Guidelines for qPCR
Special Report
Clinical Chemistry 55:4 (2009) 613
cally possible LOD should never be reported. It
also follows that results of “0” are meaningless and
misleading. LOD estimates in qPCR analyses are
complicated by the logarithmic nature of Cq, because
Cq is undefined when the template concentration
is zero. Appropriate determination and
modeling of the LOD in the qPCR is the focus of
continued research (26).
2.2 Analytical specificity refers to the qPCR assay detecting
the appropriate target sequence rather than
other, nonspecific targets also present in a sample.
Diagnostic specificity is the percentage of individuals
without a given condition whom the assay identifies
as negative for that condition.
2.3 Accuracy refers to the difference between experimentally
measured and actual concentrations,
presented as fold changes or copy number
estimates.
2.4 Repeatability (short-term precision or intraassay
variance) refers to the precision and robustness of
the assay with the same samples repeatedly analyzed
in the same assay. It may be expressed as the
SD for the Cq variance. Alternatively, the SD or the
CV for copy number or concentration variance
may be used. CVs should not be used with Cqs,
however (29).
2.5 Reproducibility (long-term precision or interassay
variance) refers to the variation in results
between runs or between different laboratories
and is typically expressed as the SD or CV of
copy numbers or concentrations. Cq values generated
from different runs are subject to inherent
interrun variation (30); hence, reporting interrun
Cq variation is not appropriate.
Publications describing mRNA concentrations for
target genes should make it clear precisely what the
targets are. The transcripts of most human genes and
many genes in other multicellular organisms are alternatively
spliced (31, 32), and these splicing variants
specify alternative protein isoforms, with variation in
splicing patterns reported in different tissues or at different
developmental stages. Consequently, single
exon–based RT-qPCR assays may detect a number of
splice variants, whereas intron-spanning primers may
be more selective but may miss some splice variants
altogether. Most recently, autosomal nonimprinted
genes that display allelic imbalance in their expression
have been described (33). Taken together, these findings
imply that use of an RT-qPCR assay that simply
targets one or at most 2 exons of an mRNA is no longer
sufficient to describe the expression level of a particular
gene. Consequently, sequence information for primers
must be provided together with an assessment of their
specificity with respect to known splice variants and
single-nucleotide polymorphism positions documented
in transcript and single-nucleotide polymorphism
databases. For primer sets selected from the
RTprimerDB database (34, 35), this is easily done by
consulting the RTprimerDB Web site (http://www.
rtprimerdb.org), which contains all the relevant information.
For commercial assays, lot information and
the providers’ experimental validation criteria are required.
The reporting of results for nonvalidated commercial
assays and assays that have been validated only
in silico are strongly discouraged.
It must be remembered that detection of the presence
of an mRNA provides no information on whether
that mRNA will be translated into a protein or, indeed,
whether a functional protein is translated at all.
Immunohistochemistry, western blotting, or
other protein-quantification methods are not always
able to corroborate quantitative cellular mRNA data.
It is now well established that there is frequently a
lack of concordance between mRNA- and proteinconcentration
data (36), which is particularly true for
mRNAs that specify proteins that are part of multifunction
protein complexes (37). Finally, it has become
clear that knowledge of the presence and function
of specific microRNAs is as important to
understanding gene expression as being able to quantify
the mRNA species (38).
It is also necessary to be aware that most quantitative
RNA data are not absolute, but relative. Thus, the
reference genes or materials used for standardization
are critical, and any assessment of the validity of an
RT-qPCR experiment must also consider the appropriateness
of the relative-quantification reference. Therefore,
the development of universal reference DNA and
RNA calibration materials, although very helpful
(39, 40), will not be a universal panacea (41, 42).
Much of the variance in reported expression values
produced in RT-qPCR experiments is not simply
due to variation in experimental protocols but is
caused by corrections applied by various dataprocessing
algorithms, each of which makes its own
assumptions about the data. Consequently, although
qPCR has frequently been proclaimed a touchstone or
a gold standard, in practice this “standard” is a variable
one, and the reporting of results requires considerable
sophistication of analysis and interpretation (43).
3. Research vs Diagnostic Applications
Applications of qPCR technology can be broadly divided
into research and diagnostic applications. Research
applications usually analyze a wide range of
targets with a fairly low throughput and many different
sample types. The main parameters that need
to be addressed relate to assay analytical sensitivity
Special Report
614 Clinical Chemistry 55:4 (2009)
and specificity, which in this context refer to how
many target copies the assay can detect and whether
the no-template controls (NTCs) are reliably negative,
respectively.
In contrast, diagnostic applications usually analyze
a limited number of targets, but require highthroughput
protocols that are targeted at only a few
sample types. Although all of the considerations that
apply to research applications also apply to diagnostic
assays, clinical-diagnostic assays have a number of additional
requirements that need to be considered.
These requirements include information on analytical
sensitivity and specificity that in this context refers to
how often the assay returns a positive result when a
target is present and how often it is negative in the
absence of the target. Furthermore, the accuracy and
precision within and between laboratories is often
monitored by external QC programs. Additional clinical
laboratory requirements include criteria for generating
reportable results, whether repeated measurements
are made on samples, data on the resolution of
false-positive/false-negative data, and the similarity of
results from multiple laboratories that use the same
and different technologies. Thus far, only a couple of
interlaboratory comparisons have been performed,
and both of these studies emphasized the need for standardization
of qPCR diagnostic assays (44, 45). Another
interlaboratory exercise is planned within the European
Framework 7 project: SPIDIA (Standardisation
and Improvement of Generic Pre-analytical Tools and
Procedures for In-Vitro Diagnostics; http://www.
spidia.eu).
4. Sample Acquisition, Handling, and Preparation
Sample acquisition constitutes the first potential
source of experimental variability, especially for experiments
targeting RNA, because mRNA profiles are easily
perturbed by sample-collection and -processing
methods. There is some suggestion that fresh tissue can
be stored on ice without major effects on RNA quality
and concentration (46), but although this supposition
may be true for some mRNAs and tissues, it may not be
universally applicable. Hence, it is better to be cautious.
Consequently, it is important to report in detail where
the tissue sample was obtained and whether it was processed
immediately. If the sample was not processed
immediately, it is necessary to report how it was preserved
and how long and under what conditions it was
stored.
A brief description of the sample is also essential.
For example, microscopical examination of a tumor
biopsy will reveal what percentage of the biopsy is made
up of tumor cells, and this information should be
reported.
Nucleic acid extraction is a second critical step.
Extraction efficiency depends on adequate homogenization,
the type of sample (e.g., in situ tissue vs logphase
cultured cells), target density, physiological status
(e.g., healthy, cancerous, or necrotic), genetic
complexity, and the amount of biomass processed.
Therefore, it necessary that details of the nucleic acid–
extraction method be provided and that the methods
used for measuring nucleic acid concentration and assessing
its quality be described. Such details are particularly
crucial for RNA extracted from fresh frozen
laser-microdissected biopsy samples, because variations
in tissue-preparation procedures have a substantial
effect on both RNA yield and quality (47).
5. QC of Nucleic Acids
5.1. RNA SAMPLES
Quantification of RNA in the extracted samples is important,
because it is advisable that approximately the
same amounts of RNA be used when comparing different
samples. There are several quantification procedures
in common use, however, including spectrophotometry
(NanoDrop; Thermo Scientific), microfluidic
analysis (Agilent Technologies’ Bioanalyzer, Bio-Rad
Laboratories’ Experion), capillary gel electrophoresis
(Qiagen’s QIAxcel), or fluorescent dye detection (Ambion/Applied
Biosystems’ RiboGreen). The methods
produce different results, making it unwise to try to
compare data obtained with the different methods
(48). The preferred method for quantifying RNA uses
fluorescent RNA-binding dyes (e.g., RiboGreen),
which are best for detecting low target concentrations.
In any case, it is advisable to measure all samples with a
single method only and to report this information.
It is also important to test for and report the extent
of genomic-DNA contamination and to record the
threshold cutoff criteria for the amounts of such contamination
that are tolerable. It is essential to report
whether the RNA sample has been treated with DNase
(including the type of DNase used and the reaction
conditions) and to report the results from a comparison
of Cqs obtained with positive and no–reverse transcription
controls for each nucleic acid target.
It is also essential to document the quality assessment
of RNA templates. The only situation in which
this requirement does not apply is when the quantity of
total RNA extracted is too low to permit quality assessment.
This situation arises when RNA is extracted from
single cells, plasma, other cell-free body fluids, some
laser-captured samples, or clarified tissue culture medium.
It also applies in cases in which extraction and
RT-qPCR steps are performed as a continuous, singletube
experiment. Key information to report includes
data on RNA quantity, integrity, and the absence of
MIQE Guidelines for qPCR
Special Report
Clinical Chemistry 55:4 (2009) 615
reverse transcription or PCR inhibitors. It is worth remembering
that RNA degrades markedly in vivo, owing
to the natural regulation of mRNAs in response to
environmental stimuli (49). This source of RNA degradation
is beyond the control of the researcher; one of
its manifestations is that even high-quality RNA samples
can show differential degradation of individual
mRNAs.
The A260/A280 ratio must be measured in a buffer
at neutral pH, but such measurement is not sufficient if
the nucleic acid is to be used for quantitative analysis,
especially when the aim is to measure minor differences
(Ͻ10-fold) in cellular mRNA concentrations.
The absorbance ratio does provide an indication of
RNA purity, because the presence of DNA or residual
phenol alters the ratio. Instead, one should provide gel
electrophoresis evidence at the least or, better yet, results
from a microfluidics-based rRNA analysis (50) or
a reference gene/target gene 3Ј:5Ј integrity assay (51).
The advantage of the use of a Bioanalyzer/Experion
system to calculate an RNA integrity number or an
RNA quality indicator number is that these measures
provide quantitative information about the general
state of the RNA sample. It is important to bear in
mind, however, that these numbers relate to rRNA
quality and cannot be expected to be an absolute measure
of quality. Use of a 3Ј:5Ј assay requires that the
PCR efficiencies of both assays be virtually identical
(51) and not be subject to differential inhibition. This
assay also necessitates the establishment of a threshold
criterion that delineates the RNA quality sufficient to
yield reliable results. Ideally, the assay should target a
panel of “integrity reference genes,” probably without
introns, with a 3Ј:5Ј threshold ratio of approximately
0.2–5. Clearly, further work is required to generate a
universally applicable, cost-effective, and simple protocol
for assessing RNA integrity.
Inhibition of reverse-transcription activity or PCR
should be checked by dilution of the sample (preferably)
or use of a universal inhibition assay such as SPUD
(52, 53). If the RNA sample is shown to be partially
degraded, it is essential that this information be reported,
because the assay’s sensitivity for detecting a
low-level transcript may be reduced and relative differences
in the degradation of transcripts may produce
incorrect target ratios.
5.2. DNA SAMPLES
In general, degradation is much less of an issue with
DNA; however, it is important to be able to assess the
extent of DNA degradation for forensic applications,
i.e., in cases in which harsh environmental conditions
at scenes of crimes or mass disasters or at sites involving
missing-person cases may have degraded the chemical
structure of DNA. The small amplicon size of qPCR
assays helps to minimize assay-related problems, but
methods have been developed that provide a quantitative
measurement of DNA quality (54) and should be
considered for such specialized purposes.
The potential for inhibition is a more generally
applicable variable that must be addressed in a publication,
and it is important to ensure that no inhibitors
copurified with the DNA will distort results, e.g.,
pathogen detection and their quantification (55). Although
such approaches such as spiking samples with
positive controls (52) can be used to detect inhibition,
different PCR reactions may not be equally susceptible
to inhibition by substances copurified in nucleic acid
extracts (56, 57). Consequently, it is better to routinely
use dilutions of nucleic acids to demonstrate that observed
decreases in Cqs or copy numbers are consistent
with the anticipated result and to report these data.
6. Reverse Transcription
The reverse-transcription step introduces substantial
variation into an RT-qPCR assay (58, 59). Hence, it is
essential that a detailed description of the protocol and
reagents used to convert RNA into cDNA be provided.
This documentation must include the amount of RNA
reverse-transcribed, priming strategy, enzyme type,
volume, temperature, and duration of the reversetranscription
step. It is recommended that the reversetranscription
step be carried out in duplicate or triplicate
and that the total RNA concentration be the same
in every sample (58).
7. qPCR
The following information must be provided for
qPCR assays: database accession numbers of each
target and reference gene, the exon locations of each
primer and any probe, the sequences and concentrations
of each oligonucleotide, including the identities,
positions, and linkages of any dyes and/or modified
bases. Also required are the concentration and
identity of the polymerase, the amount of template
(DNA or cDNA) in each reaction, the Mg2ϩ
concentration,
the exact chemical compositions of the
buffer (salts, pH, additives), and the reaction volume.
The investigators must also identify the instrument
they used and document all of the PCR cycling
conditions. Because the consumables used affect
thermal cycling, it is necessary to identify the use of
single tubes, strips, or plates, and their manufacturers.
The degree of transparency of the plasticware
used, e.g., white or clear, is also important, because
different plastics exhibit substantial differences in
fluorescence reflection and sensitivity (60). When
plates are used, the method of sealing (heat bonding
Special Report
616 Clinical Chemistry 55:4 (2009)
vs adhesives) can affect the evaporation of samples
at the plate perimeter and should therefore be
documented.
Because PCR efficiency is highly dependent on
the primers used, their sequences must be published.
This requirement is perfectly feasible even with commercial
primers, because there is a precedent for
companies to make their primer and probe sequences
available (http://www.primerdesign.co.uk/
research_with_integrity.asp).
In addition, submission to public databases
such as RTprimerDB is strongly encouraged; over
time, these databases could become universal
clearinghouses.
7.1. SECONDARY STRUCTURE
The structure of the nucleic acid target (e.g., stem and
loop secondary RNA structure) has a substantial impact
on the efficiency of reverse transcription and the
PCR. Therefore, the positions of primers, probes, and
PCR amplicons must take the folding of RNA templates
into consideration. Sequences should be checked
with nucleic acid–folding software, e.g., mfold for DNA
(http://mfold.bioinfo.rpi.edu/cgi-bin/dna-form1.cgi) or
RNA (http://frontend.bioinfo.rpi.edu/applications/
mfold/cgi-bin/rna-form1-2.3.cgi). Ideally, the folding
structures should be made available to reviewers.
7.2. SPECIFICITY
In silico tools such as BLAST or equivalent specificity
searches are useful for assay design. Any appreciable
homology to pseudogenes or other unexpected targets
should be documented and provided as aligned sequences
for review; however, specificity must be validated
empirically with direct experimental evidence
(electrophoresis gel, melting profile, DNA sequencing,
amplicon size, and/or restriction enzyme digestion).
Algorithms for predicting an oligonucleotide’s
melting temperature (Tm) are useful for initial design,
but the practical optimum temperature for annealing
must be determined experimentally. Although primer
optimization has become unfashionable, it is clear that
poor annealing optimization has a large effect on assay
quality (51). A marked presence of primer dimers produces
a lower PCR efficiency in probe-based assays and
may generate false positives in assays based on SYBR
Green I. Some evidence for primer optimization
should be provided to reviewers, ideally in the form of
annealing temperature or Mg2ϩ
gradients, and be presented
as Cq values, plots of fluorescence vs cycle number,
and/or melting curves (61).
7.3. CONTROLS AND QUANTIFICATION CALIBRATORS
In addition to the no–reverse transcription control in
RT-qPCR assays mentioned above, additional controls
and/or quantification calibrators are required for all
qPCR reactions. NTCs detect PCR contamination
when probes are used and can also distinguish unintended
amplification products (e.g., primer dimers)
from the intended PCR products in SYBR Green I reactions.
NTCs should be included on each plate or
batch of samples, and conditions for data rejection be
established. For example, NTCs with Cqs Ն40 could be
ignored if the Cq for the lowest concentration unknown
is 35.
Positive controls in the form of nucleic acids extracted
from experimental samples are useful for monitoring
assay variation over time and are essential when
calibration curves are not performed in each run.
Quantification calibrators may be purified target
molecules, such as synthetic RNA or DNA oligonucleotides
spanning the complete PCR amplicon, plasmid
DNA constructs, cDNA cloned into plasmids, RNA
transcribed in vitro, reference RNA pools, RNA or
DNA from specific biological samples, or internationally
recognized biological standards (as they become
available). Dilutions should be carried out into defined
concentrations of carrier tRNA (yeast or Escherichia
coli at 10–100 ng/␮L). For detection of human pathogens,
calibrators can be diluted into negative control
sample RNA or DNA, or they can be diluted into
healthy human plasma, after which lysis may be carried
out in the presence of carrier tRNA. Serial dilutions of a
particular template can be prepared as stock solutions
that resist several freeze–thaw cycles. A fresh batch
should be prepared when a Cq shift of 0.5–1.0 is detected.
Alternatively, solutions for calibration curves
can be stored for a week at 4 °C and then discarded.
For diagnostic assays, the qPCR should include an
independently verified calibrator, if available, that lies
within the linear interval of the assay. Positive and negative
extraction controls are also recommended.
7.4. ASSAY PERFORMANCE
The following assay performance characteristics must
be determined: PCR efficiency, linear dynamic range,
LOD, and precision.
7.4.1. PCR efficiency. Robust and precise qPCR assays
are usually correlated with high PCR efficiency. PCR
efficiency is particularly important when reporting
mRNA concentrations for target genes relative to those
of reference genes. The ⌬⌬Cq method is one of the
most popular means of determining differences in concentrations
between samples and is based on normalization
with a single reference gene. The difference in
Cq values (⌬Cq) between the target gene and the reference
gene is calculated, and the ⌬Cqs of the different
samples are compared directly. The 2 genes must be
amplified with comparable efficiencies for this comMIQE
Guidelines for qPCR
Special Report
Clinical Chemistry 55:4 (2009) 617
parison to be accurate. The most popular method is not
necessarily the most appropriate, however, and alternative,
more generalized quantitative models have
been developed to correct for differences in amplification
efficiency (62) and to allow the use of multiple
reference genes (30).
PCR amplification efficiency must be established
by means of calibration curves, because such calibration
provides a simple, rapid, and reproducible indication
of the mean PCR efficiency, the analytical sensitivity,
and the robustness of the assay. Amplification
efficiency should be determined from the slope of the
log-linear portion of the calibration curve. Specifically,
PCR efficiency ϭ 10Ϫ1/slope
Ϫ 1, when the logarithm of
the initial template concentration (the independent
variable) is plotted on the x axis and Cq (the dependent
variable) is plotted on the y axis. The theoretical maximum
of 1.00 (or 100%) indicates that the amount of
product doubles with each cycle. Ideally, the CIs or SEs
of the means of estimated PCR efficiencies are reported
from replicated calibration curves.
Calibration curves for each quantified target must
be included with the submitted manuscript so that this
information can be made available to the reviewers;
slopes and y intercepts derived from these calibration
curves must be included with the publication. Differences
in PCR efficiency will produce calibration curves
with different slopes. As a consequence, differences between
the Cq values of the targets and the references
will not remain constant as template amounts are varied,
and calculations of relative concentrations will be
inaccurate, yielding misleading results.
Cq values Ͼ40 are suspect because of the implied
low efficiency and generally should not be reported;
however, the use of such arbitrary Cq cutoffs is not
ideal, because they may be either too low (eliminating
valid results) or too high (increasing false-positive results)
(26).
7.4.2. Linear dynamic range. The dynamic range over
which a reaction is linear (the highest to the lowest
quantifiable copy number established by means of a
calibration curve) must be described. Depending on
the template used for generating calibration curves, the
dynamic range should cover at least 3 orders of magnitude
and ideally should extend to 5 or 6 log10 concentrations.
The calibration curve’s linear interval must
include the interval for the target nucleic acids being
quantified. Because lower limits of quantification are
usually poorly defined, the variation at the lowest concentration
claimed to be within the linear interval
should be determined. Correlation coefficients (r2
values) must be reported, and, ideally, CIs should be
provided through the entire linear dynamic range.
7.4.3. LOD. The LOD is defined as the lowest concentration
at which 95% of the positive samples are detected.
In other words, within a group of replicates containing
the target at concentrations at the LOD, no
more than 5% failed reactions should occur. Low-copy
PCRs are stochastically limited, and LODs of Ͻ3 copies
per PCR are not possible. If multiple reactions are performed,
however, accurate quantification of lower
concentrations can be obtained via digital PCR
(29, 63, 64). Indeed, concentration calibrators can be
checked by limiting dilution to show that the percentage
of failed and successful reactions follows a Poisson
distribution.
7.4.4. Precision. There are many explanations for variation
in qPCR results, including temperature differences
affecting the completion of annealing and/or denaturation,
concentration differences introduced by
pipetting errors, and stochastic variation. Precision in
qPCR typically varies with concentration, decreasing
with the copy number. Ideally, intraassay variation (repeatability)
should be displayed in figures as SD error
bars or as CIs on calibration curves with replicate samples.
CVs should not be used with Cqs (29) but can be
used to express the variance in copy numbers or concentrations.
This technical variation should be distinguished
from biological variation. Biological replicates
can directly address the statistical significance of differences
in qPCR results between groups or treatments.
For diagnostic assays, it may also be necessary to report
interassay precision (reproducibility) between sites
and different operators.
7.5. MULTIPLEX qPCR
The ability to multiplex greatly expands the power of
qPCR analysis (65, 66), particularly when applied to
the simultaneous detection of point mutations or polymorphisms
(67). Multiplexing requires the presentation
of evidence demonstrating that accurate quantification
of multiple targets in a single tube is not
impaired, i.e., that assay efficiency and the LOD are the
same as when the assays are run in uniplex fashion.
This concern is of particular importance when targets
of appreciably lower abundance are coamplified with
highly abundant targets.
8. Data Analysis
Data analysis includes an examination of the raw data,
an evaluation of their quality and reliability, and the
generation of reportable results. Various datacollection
and -processing strategies have been described,
and a systematic evaluation has revealed that
qPCR data-analysis methods differ substantially in
their performance (68).
Special Report
618 Clinical Chemistry 55:4 (2009)
Detailed information on the methods of data analysis
and confidence estimation is necessary, together
with specification of the software used. The methods of
identifying outliers and the disposition of such data
must be specified. Documenting assay precision requires
identification of the statistical methods used to
evaluate variances (e.g., 95% CIs) and presentation of
the corresponding concentrations or Cq values. Such
information should include both repeatability and reproducibility
data, if available. As discussed above, reporting
of CVs for Cqs is inappropriate (29), because
Cqs will always be lower (and therefore potentially misleading)
than CVs calculated for copy numbers. Information
must be provided on the methods used for assessing
accuracy, including the statistical significance
of reported differences between groups.
8.1. NORMALIZATION
Normalization is an essential component of a reliable
qPCR assay because this process controls for variations
in extraction yield, reverse-transcription yield, and efficiency
of amplification, thus enabling comparisons of
mRNA concentrations across different samples. The
use of reference genes as internal controls is the most
common method for normalizing cellular mRNA data;
however, although the use of reference genes is commonly
accepted as the most appropriate normalization
strategy (69), their utility must be experimentally validated
for particular tissues or cell types and specific
experimental designs. Unfortunately, although there is
an increased awareness of the importance of systematic
validation and although the potentially highly misleading
effects of the use of inappropriate reference genes
for normalization are widely known, these considerations
also are still widely disregarded (70). Consequently,
many molecular analyses still contain qPCR
data that are poorly normalized.
Normalization involves reporting the ratios of the
mRNA concentrations of the genes of interest to those
of the reference genes. Reference gene mRNAs should
be stably expressed, and their abundances should show
strong correlation with the total amounts of mRNA
present in the samples.
Normalization against a single reference gene is
not acceptable unless the investigators present clear evidence
for the reviewers that confirms its invariant expression
under the experimental conditions described.
The optimal number and choice of reference genes
must be experimentally determined and the method
reported (71–73).
8.2. VARIABILITY
The inherent variability of biological systems may rival
or exceed experimental differences between groups.
This variation is often observed when many biological
replicates are used to increase the statistical significance
of the experiment. Although differences between biological
replicates may be large, sufficient numbers may
allow smaller experimental differences to be discerned.
A recent publication provides a textbook example for
handling such data and how to salvage biologically
meaningful data from assays subject to high biological
variation (74). Many factors contribute to experimental
variation and influence the number of biological
replicates necessary to achieve a given statistical power.
Consequently, power analysis is useful for determining
the number of samples necessary for valid conclusions.
8.3. QUALITATIVE ANALYSIS
The use of the PCR to detect merely the presence of a
nucleic acid template, rather than to quantify it accurately,
is referred to as qualitative PCR, which is widely
used in pathogen diagnostics. The problem with qualitative/quantitative
stratification of PCR methods is
that an accurate yes/no answer requires information
about the low-end sensitivity of the PCR assay. Consequently,
even a qualitative assay should provide information
about the assay’s performance characteristics,
especially with respect to the points discussed in sections
7.4.2. and 7.4.3.
Conclusions
The necessity for ensuring quality-assurance measures
for qPCR and RT-qPCR assays is well recognized
(25, 44, 75–86). The main difference between qPCR
and conventional (legacy) PCR assays is the expectation
of the former’s potential to quantify target nucleic
acids accurately. This difference must be clearly recognized,
and one cannot assume that legacy PCR assays
can translate directly into the qPCR format. Table 1
provides a checklist for authors preparing a report of a
qPCR study. Items deemed essential (E) are required to
allow reviewers to evaluate the work and other investigators
to reproduce it. Items considered desirable (D)
are also important and should be included if possible,
but they may not be available in all cases. Certainly, it is
important to apply common sense: Compliance with
all items on the checklist is not necessary for initial
screening of expression signatures targeting hundreds
of targets. Once a more limited set of targets (fewer
than 20) has been identified, however, assay performance
should be described as detailed by the checklist,
which is hosted on http://www.rdml.org/miqe/.
In summary, the purpose of these guidelines is
3-fold:
1. To enable authors to design and report qPCR experiments
that have greater inherent value.
MIQE Guidelines for qPCR
Special Report
Clinical Chemistry 55:4 (2009) 619
2. To allow reviewers and editors to measure the technical
quality of submitted manuscripts against an established
yardstick.
3. To facilitate easier replication of experiments described
in published studies that follow these guidelines.
As a consequence, investigations that use this
widely applied technology will produce data that are
more uniform, more comparable, and, ultimately,
more reliable.
Author Contributions: All authors confirmed they have contributed to
the intellectual content of this paper and have met the following 3 requirements:
(a) significant contributions to the conception and design,
acquisition of data, or analysis and interpretation of data; (b) drafting
or revising the article for intellectual content; and (c) final approval of
the published article.
Authors’ Disclosures of Potential Conflicts of Interest: Upon
manuscript submission, all authors completed the Disclosures of Potential
Conflict of Interest form. Potential conflicts of interest:
EmploymentorLeadership:J.Hellemans,Biogazelle;J.Vandesompele,
Biogazelle; C.T. Wittwer, Idaho Technology.
Consultant or Advisory Role: R. Mueller, DermTech International.
Stock Ownership: R. Mueller, Sequenom; C.T. Wittwer, Idaho
Technology.
Honoraria: None declared.
Research Funding: S.A. Bustin, Bowel and Cancer Research, registered
charity number 1119105; J. Hellemans, Fund for Scientific Research
Flanders; M. Kubista, grant agency of the Academy of Sciences,
Czech Republic (grants IAA500520809 and AV0250520701);
C.T. Wittwer, ARUP Institute for Clinical and Experimental Pathology
and Idaho Technology.
Expert Testimony: None declared.
Role of Sponsor: The funding organizations played no role in the
design of study, choice of enrolled patients, review and interpretation
of data, or preparation or approval of manuscript.
References
1. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous
amplification and detection of specific
DNA sequences. Biotechnology (N Y) 1992;
10:413–7.
2. Higuchi R, Fockler C, Dollinger G, Watson R.
Kinetic PCR analysis: real-time monitoring of DNA
amplification reactions. Biotechnology (N Y)
1993;11:1026–30.
3. Wittwer CT, Herrmann MG, Moss AA, Rasmussen
RP. Continuous fluorescence monitoring of rapid
cycle DNA amplification. Biotechniques 1997;22:
130–8.
4. Bustin SA. Absolute quantification of mRNA
using real-time reverse transcription polymerase
chain reaction assays. J Mol Endocrinol
2000;25:169–93.
5. Kubista M, Andrade JM, Bengtsson M, Forootan
A, Jonak J, Lind K, et al. The real-time polymerase
chain reaction. Mol Aspects Med 2006;27:95–
125.
6. Bernard PS, Wittwer CT. Real-time PCR technology
for cancer diagnostics. Clin Chem 2002;48:
1178–85.
7. Mackay IM, Arden KE, Nitsche A. Real-time PCR
in virology. Nucleic Acids Res 2002;30:1292–305.
8. Mackay IM. Real-time PCR in the microbiology
laboratory. Clin Microbiol Infect 2004;10:190–
212.
9. Bustin SA, Mueller R. Real-time reverse transcription
PCR (qRT-PCR) and its potential use in
clinical diagnosis. Clin Sci (Lond) 2005;109:
365–79.
10. Bustin SA, Mueller R. Real-time reverse transcription
PCR and the detection of occult disease in
colorectal cancer. Mol Aspects Med 2006;27:
192–223.
11. van den Berg RJ, Vaessen N, Endtz HP, Schulin T,
van der Vorm ER, Kuijper EJ. Evaluation of realtime
PCR and conventional diagnostic methods
for the detection of Clostridium difficileassociated
diarrhoea in a prospective multicentre
study. J Med Microbiol 2007;56:36–42.
12. Bustin SA, Nolan T. Pitfalls of quantitative realtime
reverse-transcription polymerase chain reaction.
J Biomol Tech 2004;15:155–66.
13. Garson JA, Huggett JF, Bustin SA, Pfaffl MW,
Benes V, Vandesompele J, Shipley GL. Unreliable
real-time PCR analysis of human endogenous
retrovirus-W (HERV-W) RNA expression and DNA
copy number in multiple sclerosis. AIDS Res Hum
Retroviruses. Forthcoming 2009.
14. Huang T, Bohlenius H, Eriksson S, Parcy F, Nilsson
O. The mRNA of the Arabidopsis gene FT moves
from leaf to shoot apex and induces flowering.
Science 2005;309:1694–6.
15. Bohlenius H, Eriksson S, Parcy F, Nilsson O.
Retraction. Science 2007;316:367.
16. Brazma A, Hingamp P, Quackenbush J, Sherlock
G, Spellman P, Stoeckert C, et al. Minimum
information about a microarray experiment
(MIAME)—toward standards for microarray data.
Nat Genet 2001;29:365–71.
17. Taylor CF, Paton NW, Lilley KS, Binz PA, Julian RK
Jr, Jones AR, et al. The minimum information
about a proteomics experiment (MIAPE). Nat Biotechnol
2007;25:887–93.
18. Field D, Garrity G, Gray T, Morrison N, Selengut J,
Sterk P, et al. The minimum information about a
genome sequence (MIGS) specification. Nat Biotechnol
2008;26:541–7.
19. Echeverri CJ, Beachy PA, Baum B, Boutros M,
Buchholz F, Chanda SK, et al. Minimizing the risk
of reporting false positives in large-scale RNAi
screens. Nat Methods 2006;3:777–9.
20. Haney SA. Increasing the robustness and validity
of RNAi screens. Pharmacogenomics 2007;8:
1037–49.
21. Sansone SA, Fan T, Goodacre R, Griffin JL, Hardy
NW, Kaddurah-Daouk R, et al. The metabolomics
standards initiative. Nat Biotechnol 2007;25:846–8.
22. Taylor CF, Field D, Sansone SA, Aerts J, Apweiler
R, Ashburner M, et al. Promoting coherent minimum
reporting guidelines for biological and biomedical
investigations: the MIBBI project. Nat
Biotechnol 2008;26:889–96.
23. Burns MJ, Valdivia H, Harris N. Analysis and
interpretation of data from real-time PCR trace
detection methods using quantitation of GM soya
as a model system. Anal Bioanal Chem 2004;378:
1616–23.
24. Burns MJ, Nixon GJ, Foy CA, Harris N. Standardisation
of data from real-time quantitative PCR
methods – evaluation of outliers and comparison
of calibration curves. BMC Biotechnol 2005;5:31.
25. Ellison SL, English CA, Burns MJ, Keer JT. Routes
to improving the reliability of low level DNA
analysis using real-time PCR. BMC Biotechnol
2006;6:33.
26. Burns MJ, Valdivia H. Modelling the limit of detection
in real-time quantitative PCR. Eur Food
Res Technol 2008;226:1513–24.
27. Lefever S, Hellemans J, Pattyn F, Przybylski DR,
Taylor C, Geurts R, et al. RDML: structured language
and reporting guidelines for real-time quantitative
PCR data. Nucleic Acids Res [Epub ahead of print
2009 Feb 17]. Available at: http://nar.oxfordjournals.
org/cgi/content/abstract/gkp056.
28. Wittwer CT, Kusakawa N. Real-time PCR. In:
Persing DH, Tenover FC, Versalovic J, Tang JW,
Unger ER, Relman DA, White TJ, eds. Molecular
microbiology: diagnostic principles and practice.
Washington: ASM Press; 2004. p 71–84.
29. Schmittgen TD, Livak KJ. Analyzing real-time PCR
data by the comparative CT method. Nat Protoc
2008;3:1101–8.
30. Hellemans J, Mortier G, De Paepe A, Speleman F,
Vandesompele J. qBase relative quantification
framework and software for management and
automated analysis of real-time quantitative PCR
data. Genome Biol 2007;8:R19.
31. de la Grange P, Dutertre M, Correa M, Auboeuf
D. A new advance in alternative splicing
databases: from catalogue to detailed analysis of
regulation of expression and function of human
alternative splicing variants. BMC Bioinformatics
2007;8:180.
32. Ben-Dov C, Hartmann B, Lundgren J, Valcarcel
J. Genome-wide analysis of alternative pre-mRNA
splicing. J Biol Chem 2008;283:1229–33.
33. Bjornsson HT, Albert TJ, Ladd-Acosta CM, Green
RD, Rongione MA, Middle CM, et al. SNP-specific
array-based allele-specific expression analysis.
Genome Res 2008;18:771–9.
34. Pattyn F, Robbrecht P, De Paepe A, Speleman F,
Vandesompele J. RTPrimerDB: the real-time PCR
Special Report
620 Clinical Chemistry 55:4 (2009)
primer and probe database, major update 2006.
Nucleic Acids Res 2006;34:D684–8.
35. Pattyn F, Speleman F, De Paepe A, Vandesompele
J. RTPrimerDB: the real-time PCR primer and
probe database. Nucleic Acids Res 2003;31:
122–3.
36. Gygi SP, Rochon Y, Franza BR, Aebersold R.
Correlation between protein and mRNA abundance
in yeast. Mol Cell Biol 1999;19:1720–30.
37. Schmidt MW, Houseman A, Ivanov AR, Wolf DA.
Comparative proteomic and transcriptomic profiling
of the fission yeast Schizosaccharomyces
pombe. Mol Syst Biol 2007;3:79.
38. Landi D, Gemignani F, Naccarati A, Pardini B,
Vodicka P, Vodickova L, et al. Polymorphisms
within micro-RNA-binding sites and risk of sporadic
colorectal cancer. Carcinogenesis 2008;29:
579–84.
39. Cronin M, Ghosh K, Sistare F, Quackenbush J,
Vilker V, O’Connell C. Universal RNA reference
materials for gene expression. Clin Chem 2004;
50:1464–71.
40. Novoradovskaya N, Whitfield ML, Basehore LS,
Novoradovsky A, Pesich R, Usary J, et al. Universal
Reference RNA as a standard for microarray
experiments. BMC Genomics 2004;5:20.
41. Gingeras TR. RNA reference materials for gene
expression studies. Difficult first steps. Clin Chem
2004;50:1289–90.
42. Joseph LJ. RNA reference materials for gene expression
studies. RNA metrology: forecast calls
for partial clearing. Clin Chem 2004;50:1290–2.
43. Bustin SA, Benes V, Nolan T, Pfaffl MW. Quantitative
real-time RT-PCR—a perspective. J Mol
Endocrinol 2005;34:597–601.
44. Ramsden SC, Daly S, Geilenkeuser WJ, Duncan G,
Hermitte F, Marubini E, et al. EQUAL-quant: an
international external quality assessment scheme
for real-time PCR. Clin Chem 2006;52:1584–91.
45. Damond F, Benard A, Ruelle J, Alabi A, Kupfer B,
Gomes P, et al. Quality control assessment of
human immunodeficiency virus type 2 (HIV-2)
viral load quantification assays: results from an
international collaboration on HIV-2 infection in
2006. J Clin Microbiol 2008;46:2088–91.
46. Micke P, Ohshima M, Tahmasebpoor S, Ren ZP,
Ostman A, Ponten F, Botling J. Biobanking of
fresh frozen tissue: RNA is stable in nonfixed
surgical specimens. Lab Invest 2006;86:202–11.
47. Morrogh M, Olvera N, Bogomolniy F, Borgen PI,
King TA. Tissue preparation for laser capture
microdissection and RNA extraction from fresh
frozen breast tissue. Biotechniques 2007;43:
41–2, 4, 6 passim.
48. Bustin SA. Real-time, fluorescence-based quantitative
PCR: a snapshot of current procedures and
preferences. Expert Rev Mol Diagn 2005;5:
493–8.
49. Doma MK, Parker R. RNA quality control in eukaryotes.
Cell 2007;131:660–8.
50. Fleige S, Pfaffl MW. RNA integrity and the effect
on the real-time qRT-PCR performance. Mol Aspects
Med 2006;27:126–39.
51. Nolan T, Hands RE, Bustin SA. Quantification of
mRNA using real-time RT-PCR. Nat Protoc 2006;
1:1559–82.
52. Nolan T, Hands RE, Ogunkolade BW, Bustin SA.
SPUD: a qPCR assay for the detection of inhibitors
in nucleic acid preparations. Anal Biochem 2006;
351:308–10.
53. Ferns RB, Garson JA. Development and evaluation
of a real-time RT-PCR assay for quantification
of cell-free human immunodeficiency virus
type 2 using a brome mosaic virus internal control.
J Virol Methods 2006;135:102–8.
54. Swango KL, Hudlow WR, Timken MD, Buoncristiani
MR. Developmental validation of a multiplex
qPCR assay for assessing the quantity and quality
of nuclear DNA in forensic samples. Forensic Sci
Int 2007;170:35–45.
55. Garson JA, Grant PR, Ayliffe U, Ferns RB, Tedder
RS. Real-time PCR quantitation of hepatitis B
virus DNA using automated sample preparation
and murine cytomegalovirus internal control. J
Virol Methods 2005;126:207–13.
56. Huggett JF, Novak T, Garson JA, Green C, MorrisJones
SD, Miller RF, Zumla A. Differential susceptibility
of PCR reactions to inhibitors: an important
and unrecognised phenomenon. BMC Res
Notes 2008;1:70.
57. Ståhlberg A, Aman P, Ridell B, Mostad P, Kubista
M. Quantitative real-time PCR method for detection
of B-lymphocyte monoclonality by comparison
of ␬ and ␭ immunoglobulin light chain expression.
Clin Chem 2003;49:51–9.
58. Ståhlberg A, Hakansson J, Xian X, Semb H,
Kubista M. Properties of the reverse transcription
reaction in mRNA quantification. Clin Chem
2004;50:509–15.
59. Ståhlberg A, Kubista M, Pfaffl M. Comparison of
reverse transcriptases in gene expression analysis.
Clin Chem 2004;50:1678–80.
60. Reiter M, Pfaffl M. Effects of plate position, plate
type and sealing systems on real-time PCR results.
Biotechnol Biotechnol Equip 2008;22:
824–8.
61. Ririe KM, Rasmussen RP, Wittwer CT. Product
differentiation by analysis of DNA melting curves
during the polymerase chain reaction. Anal Biochem
1997;245:154–60.
62. Pfaffl MW. A new mathematical model for relative
quantification in real-time RT-PCR. Nucleic
Acids Res 2001;29:E45.
63. Dube S, Qin J, Ramakrishnan R. Mathematical
analysis of copy number variation in a DNA sample
using digital PCR on a nanofluidic device.
PLoS ONE 2008;3:e2876.
64. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl
Acad Sci U S A 1999;96:9236–41.
65. Elnifro EM, Ashshi AM, Cooper RJ, Klapper PE.
Multiplex PCR: optimization and application in
diagnostic virology. Clin Microbiol Rev 2000;13:
559–70.
66. Wittwer CT, Herrmann MG, Gundry CN,
Elenitoba-Johnson KS. Real-time multiplex PCR
assays. Methods 2001;25:430–42.
67. Elenitoba-Johnson KS, Bohling SD, Wittwer CT,
King TC. Multiplex PCR by multicolor fluorimetry
and fluorescence melting curve analysis. Nat Med
2001;7:249–53.
68. Karlen Y, McNair A, Perseguers S, Mazza C, Mermod
N. Statistical significance of quantitative
PCR. BMC Bioinformatics 2007;8:131.
69. Huggett J, Dheda K, Bustin S, Zumla A. Real-time
RT-PCR normalisation; strategies and considerations.
Genes Immun 2005;6:279–84.
70. Gutierrez L, Mauriat M, Guenin S, Pelloux J,
Lefebvre JF, Louvet R, et al. The lack of a systematic
validation of reference genes: a serious pitfall
undervalued in reverse transcription-polymerase
chain reaction (RT-PCR) analysis in plants. Plant
Biotechnol J 2008;6:609–18.
71. Vandesompele J, De Preter K, Pattyn F, Poppe
B, Van Roy N, De Paepe A, Speleman F. Accurate
normalization of real-time quantitative RTPCR
data by geometric averaging of multiple
internal control genes. Genome Biol 2002;3:
RESEARCH0034.
72. Pfaffl MW, Horgan GW, Dempfle L. Relative expression
software tool (REST) for group-wise
comparison and statistical analysis of relative
expression results in real-time PCR. Nucleic Acids
Res 2002;30:e36.
73. Andersen CL, Jensen JL, Orntoft TF. Normalization
of real-time quantitative reverse transcriptionPCR
data: a model-based variance estimation
approach to identify genes suited for normalization,
applied to bladder and colon cancer data
sets. Cancer Res 2004;64:5245–50.
74. Willems E, Leyns L, Vandesompele J. Standardization
of real-time PCR gene expression data
from independent biological replicates. Anal Biochem
2008;379:127–9.
75. Apfalter P, Reischl U, Hammerschlag MR. Inhouse
nucleic acid amplification assays in
research: How much quality control is needed
before one can rely upon the results? J Clin
Microbiol 2005;43:5835–41.
76. Ciabatti I, Froiio A, Gatto F, Amaddeo D,
Marchesi U. In-house validation and quality control
of real-time PCR methods for GMO detection:
a practical approach. Dev Biol (Basel) 2006;126:
79–86; discussion 324–5.
77. de Cremoux P, Bieche I, Tran-Perennou C, Vignaud
S, Boudou E, Asselain B, et al. Inter-laboratory
quality control for hormone-dependent gene expression
in human breast tumors using real-time
reverse transcription-polymerase chain reaction.
Endocrine Relat Cancer 2004;11:489–95.
78. de Vries TJ, Fourkour A, Punt CJ, van de Locht LT,
Wobbes T, van den Bosch S, et al. Reproducibility
of detection of tyrosinase and MART-1 transcripts
in the peripheral blood of melanoma patients: a
quality control study using real-time quantitative
RT-PCR. Br J Cancer 1999;80:883–91.
79. Gabert J, Beillard E, van der Velden VH, Bi W,
Grimwade D, Pallisgaard N, et al. Standardization
and quality control studies of ‘real-time’ quantitative
reverse transcriptase polymerase chain reaction
of fusion gene transcripts for residual disease
detection in leukemia – a Europe Against
Cancer program. Leukemia 2003;17:2318–57.
80. Lemmer K, Donoso Mantke O, Bae HG, Groen J,
Drosten C, Niedrig M. External quality control
assessment in PCR diagnostics of dengue virus
infections. J Clin Virol 2004;30:291–6.
81. Marubini E, Verderio P, Raggi CC, Pazzagli M,
Orlando C. Statistical diagnostics emerging from
external quality control of real-time PCR. Int J Biol
Markers 2004;19:141–6.
82. Raggi CC, Verderio P, Pazzagli M, Marubini E,
Simi L, Pinzani P, et al. An Italian program of
external quality control for quantitative assays
based on real-time PCR with Taq-Man probes.
Clin Chem Lab Med 2005;43:542–8.
83. Sjoholm MI, Dillner J, Carlson J. Assessing quality
and functionality of DNA from fresh and archival
dried blood spots and recommendations for quality
control guidelines. Clin Chem 2007;53:
1401–7.
MIQE Guidelines for qPCR
Special Report
Clinical Chemistry 55:4 (2009) 621
84. Wang X, Jia S, Meyer L, Xiang B, Chen LY, Jiang
N, et al. Comprehensive quality control utilizing
the prehybridization third-dye image leads
to accurate gene expression measurements by
cDNA microarrays. BMC Bioinformatics 2006;
7:378.
85. Winters MA, Tan LB, Katzenstein DA, Merigan
TC. Biological variation and quality control of
plasma human immunodeficiency virus type 1
RNA quantitation by reverse transcriptase polymerase
chain reaction. J Clin Microbiol 1993;31:
2960–6.
86. van der Velden VH, Panzer-Grumayer ER, Cazzaniga
G, Flohr T, Sutton R, Schrauder A, et al.
Optimization of PCR-based minimal residual disease
diagnostics for childhood acute lymphoblastic
leukemia in a multi-center setting. Leukemia
2007;21:706–13.
Special Report
622 Clinical Chemistry 55:4 (2009)